Prognostic significance of copy number gains of MYC detected by fluorescence in situ hybridization in large B-cell lymphoma

References

• Baluapuri A, Wolf E, Eilers M. Target gene-independent functions of MYC oncoproteins. Nat Rev Mol Cell Biol. 2020;21(5):255–267. doi:10.1038/s41580-020-0215-2
   PubMed Web of Science ®Google Scholar
• Chen H, Liu H, Qing G. Targeting oncogenic myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5.
   PubMed Web of Science ®Google Scholar
• Kalkat M, De Melo J, Hickman KA, et al. MYC deregulation in primary human cancers. Genes (Basel). 2017;8(6):151. doi:10.3390/genes8060151
   PubMed Web of Science ®Google Scholar
• Xia Y, Zhang X. The spectrum of MYC alterations in diffuse large B-cell lymphoma. Acta Haematol. 2020;143(6):520–528. doi:10.1159/000505892
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL. World health organization classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, 2017.
   Google Scholar
• Landsburg DJ, Falkiewicz MK, Petrich AM, et al. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Br J Haematol. 2016;175(4):631–640. doi:10.1111/bjh.14282
   PubMed Web of Science ®Google Scholar
• Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012;7(4):e33813. doi:10.1371/journal.pone.0033813
   PubMed Web of Science ®Google Scholar
• Schrader A, Bentink S, Spang R, et al. High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. Int J Cancer. 2012;131(4):E348–61. doi:10.1002/ijc.26423
   PubMed Web of Science ®Google Scholar
• Steven H, Swerdlow EC, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. 2017, Lyon: stylus Publishing, LLC. 585.
   Google Scholar
• Copie-Bergman C, Cuillière-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126(22):2466–2474. doi:10.1182/blood-2015-05-647602
   PubMed Web of Science ®Google Scholar
• Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;124(24):4622–4632. doi:10.1002/cncr.31646
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Chang JE, et al. NCCN guidelines® insights: b-Cell lymphomas, version 5.2021: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2021;19(11):1218–1230. doi:10.6004/jnccn.2021.0054
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Pillai RK, Sathanoori M, Van Oss SB, et al. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013;37(3):323–332. doi:10.1097/PAS.0b013e31826cebad
   PubMed Web of Science ®Google Scholar
• Schrader AMR, Jansen PM, Vermeer MH, et al. High incidence and clinical significance of MYC rearrangements in primary cutaneous diffuse large B-Cell lymphoma, leg type. Am J Surg Pathol. 2018;42(11):1488–1494. doi:10.1097/PAS.0000000000001132
   PubMed Web of Science ®Google Scholar
• Aukema SM, Kreuz M, Kohler CW, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular burkitt lymphoma. Haematologica. 2014;99(4):726–735. doi:10.3324/haematol.2013.091827
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Petrich AM, Abramson JS, et al. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Cancer. 2016;122(4):559–564. doi:10.1002/cncr.29781
   PubMed Web of Science ®Google Scholar
• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–1253. doi:10.1182/blood.2022015851
   PubMed Web of Science ®Google Scholar
• Pophali PA, Marinelli LM, Ketterling RP, et al. High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease? Blood Cancer J. 2020;10(1):5. doi:10.1038/s41408-019-0271-z
   PubMed Web of Science ®Google Scholar
• Quesada AE, Medeiros LJ, Desai PA, et al. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017;30(12):1688–1697. doi:10.1038/modpathol.2017.93
   PubMed Web of Science ®Google Scholar
• Schieppati F, Balzarini P, Fisogni S, et al. An increase in MYC copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens. Haematologica. 2020;105(5):1369–1378. doi:10.3324/haematol.2019.223891
   PubMed Web of Science ®Google Scholar
• Sermer D, Bobillo S, Dogan A, et al. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. Blood Adv. 2020;4(14):3382–3390. doi:10.1182/bloodadvances.2020001551
   PubMed Web of Science ®Google Scholar
• Huang S, Nong L, Wang W, et al. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma. Diagn Pathol. 2019;14(1):81. doi:10.1186/s13000-019-0856-7
   PubMedGoogle Scholar
• Valera A, López-Guillermo A, Cardesa-Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013;98(10):1554–1562. doi:10.3324/haematol.2013.086173
   PubMed Web of Science ®Google Scholar
• Testoni M, Kwee I, Greiner TC, et al. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Br J Haematol. 2011;155(2):274–277. doi:10.1111/j.1365-2141.2011.08675.x
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Haynes, W., Bonferroni correction., In Encyclopedia of systems biology. W. Dubitzky, et al. Editors. 2013. Springer: New York, NY. p. 154–154.
   Google Scholar
• Wickham H. ggplot2: elegant graphics for data analysis. 2016: Springer-Verlag: New York.
   Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842. doi:10.1182/blood-2013-09-524108
   PubMed Web of Science ®Google Scholar
• Nguyen L, Papenhausen P, Shao H. The role of c-MYC in B-Cell lymphomas: diagnostic and molecular aspects. Genes, 2017;8(4):116. doi:10.3390/genes8040116
   PubMed Web of Science ®Google Scholar
• Sewastianik T, Prochorec-Sobieszek M, Chapuy B, et al. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. Biochim Biophys Acta. 2014;1846(2):457–467. doi:10.1016/j.bbcan.2014.08.006
   PubMed Web of Science ®Google Scholar
• Lu T-X, Fan L, Wang L, et al. MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. Oncotarget. 2015;6(21):18374–18388. doi:10.18632/oncotarget.4073
   PubMed Web of Science ®Google Scholar
• Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal Centre-like B cell (GCB) type. Histopathology. 2008;53(2):205–217. doi:10.1111/j.1365-2559.2008.03076.x
   PubMed Web of Science ®Google Scholar
• Tanaka K, Goto H, Nishimura Y, et al. Tetraploidy in cancer and its possible link to aging. Cancer Sci. 2018;109(9):2632–2640. doi:10.1111/cas.13717
   PubMed Web of Science ®Google Scholar
• Krull JE, Wenzl K, Hartert KT, et al. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Blood Cancer J. 2020;10(11):117. doi:10.1038/s41408-020-00382-3
   PubMed Web of Science ®Google Scholar
• Stasik CJ, Nitta H, Zhang W, et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica. 2010;95(4):597–603. doi:10.3324/haematol.2009.012864
   PubMed Web of Science ®Google Scholar
• Collinge B, Ben-Neriah S, Chong L, et al. The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood. 2021;137(16):2196–2208. doi:10.1182/blood.2020007193
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–3459. doi:10.1200/JCO.2011.41.0985
   PubMed Web of Science ®Google Scholar
• Herrera AF, Mei M, Low L, et al. Relapsed or refractory Double-Expressor and Double-Hit lymphomas have inferior Progression-Free survival after autologous Stem-Cell transplantation. J Clin Oncol. 2017;35(1):24–31. doi:10.1200/JCO.2016.68.2740
   PubMed Web of Science ®Google Scholar